Molly Stirling ’25 pitched Abbott Laboratories (NYSE: ABT) on March 24, 2025. Abbott Laboratories, founded in 1888 and headquartered in Lake County, Illinois, is a global healthcare leader that helps people live more fully at all stages of life. The company discovers, develops, manufactures, and sells a broad and diversified line of healthcare products and services. Abbott Laboratories’ products include generic pharmaceuticals, pediatric and adult nutritional products, diagnostic systems and tests, devices for treating cardiovascular diseases and diabetes, and neuromodulation devices for chronic pain and movement disorder management. Abbott Laboratories’ four major businesses include Nutrition, Diagnostics, Medical Devices, and Established Pharmaceuticals.
Molly’s investment thesis highlighted Abbott Laboratories’ strong growth and stability, their diversification of products and markets, and the positive medical devices segment outlook. Looking forward, Abbott Laboratories plans to introduce new versions of existing devices, achieve key milestones in clinical trials, and expand indications for its treatments. As a leader across multiple healthcare sectors, Abbott Laboratories reduces risks tied to reliance on any single business unit, creating multiple growth opportunities across different markets. The company is well-positioned to capitalize on the medical devices segment trends, such as procedures becoming faster, less invasive, and more accessible. Products that contribute to their strong performance in the medical devices segment include FreeStyle Libre, Navitor, TriClip, Amplatzer Amulet, and AVEIR.
SMIF voted to purchase approximately $65,000 of ABT, funded through the partial sale of their XLV holding.
Leave a Reply